CNS Pharmaceuticals, Inc.
CNSP
$6.66
$0.152.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.10M | 5.42M | 5.59M | 5.61M | 5.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.20M | 15.58M | 15.69M | 14.90M | 17.08M |
| Operating Income | -13.20M | -15.58M | -15.69M | -14.90M | -17.08M |
| Income Before Tax | -13.07M | -15.46M | -15.61M | -14.86M | -17.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.07 | -15.46 | -15.61 | -14.86 | -17.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.07M | -15.46M | -15.61M | -14.86M | -17.06M |
| EBIT | -13.20M | -15.58M | -15.69M | -14.90M | -17.08M |
| EBITDA | -13.20M | -15.57M | -15.69M | -14.90M | -17.08M |
| EPS Basic | -66.59 | -214.03 | -207.62 | -188.69 | -153.20 |
| Normalized Basic EPS | -41.62 | -133.77 | -129.76 | -117.93 | -95.75 |
| EPS Diluted | -66.69 | -214.13 | -207.71 | -188.75 | -153.20 |
| Normalized Diluted EPS | -41.62 | -133.77 | -129.76 | -117.93 | -95.75 |
| Average Basic Shares Outstanding | 1.25M | 723.40K | 353.30K | 126.10K | 36.60K |
| Average Diluted Shares Outstanding | 1.25M | 723.40K | 353.30K | 126.10K | 36.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |